Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin

Larry Smith(Vical (United States)), Ronald B. Moss(Vical (United States)), Alice Chu(Vical (United States)), Ernest R. Kitt(Vical (United States)), Robert B. Belshe(Saint Louis University), Martin L. Kabongo(University of California San Diego), Casey E. Dunne(Vical (United States)), Souphaphone Boutsaboualoy(Vical (United States)), Denis Rusalov(Vical (United States)), Luane Reyes(Vical (United States)), Ming Ye(Florida State University), Cindy L. Fisher(Vical (United States)), Roy T. Steigbigel(Stony Brook University), Mohamed Al‐Ibrahim, Jennifer A. Chaplin(Vical (United States)), Alain Rolland(Fonctions Optiques pour les Technologies de l’information), Mary K. Wloch(Vical (United States))
Vaccine
February 1, 2010
Cited by 142


Related Papers